SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

LY2562175

Item No. 28912

CAS Registry No.:	1103500-20-4
Formal Name:	6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl] methoxy]-1-piperidinyl]-1-methyl-1H-indole-3-carboxylic acid
MF:	$C_{28}H_{27}Cl_2N_3O_4$
FW:	540.4
Purity:	≥95%
UV/Vis.:	λ_{max}: 244 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LY2562175 is supplied as a crystalline solid. A stock solution may be made by dissolving the LY2562175 in the solvent of choice, which should be purged with an inert gas. LY2562175 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of LY2562175 in these solvents is approximately 30 and 20 mg/ml, respectively.

LY2562175 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LY2562175 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. LY2562175 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LY2562175 is a farnesoid X receptor (FXR) agonist (EC_{50} = 193 nM in a reporter assay).[1] It is selective for FXR over the glucocorticoid, androgen, mineralocorticoid, and progesterone receptors in HEK293 cells overexpressing the human receptors (EC_{50}s = >10 µM for all in a radioligand binding assay). LY2562175 increases the interaction between FXR and steroid receptor coactivator 1 (SRC-1) with an EC_{50} value of 121 nM in a cell-free assay. It reduces plasma triglyceride and total cholesterol levels in LDL receptor-null mice (ED_{50}s = 3.4 and 2 mg/kg, respectively). LY2562175 also decreases plasma LDL and increases HDL levels in Zucker diabetic fatty (ZDF) rats when administered at doses of 3, 10, and 30 mg/kg for nine days.

Reference

1. Genin, M.J., Bueno, A.B., Francisco, J.A., *et al.* Discovery of 6-(4-{[5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1*H*-indole-3-carboxylic acid: A novel FXR agonist for the treatment of dyslipidemia. *J. Med. Chem.* **58(24)**, 9768-9772 (2015).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM